Suppression of benign prostate hyperplasia by *Kaempferia parviflora* rhizome

Kazuya Murata, Hirotaka Hayashi¹, Shinichi Matsumura², Hideaki Matsuda

Faculty of Pharmacy, Kinki University, 3-4-1 Kowakae, Higashiosaka, Osaka 577-8502, ¹Japan Tablet Corporation, 149-1 Mekawa, Makishima, Uji, Kyoto 611-0041, ²Inabata Koryo Co., Ltd, 3-5-20 Tagawa, Yodogawa-ku, Osaka 532-0027, Japan

Submitted: 12-01-2013 Revised: 13-03-2013 Published: 24-09-2013

**ABSTRACT**

Background: *Kaempferia parviflora* rhizome is used as a folk medicine in Thailand for the treatment of various symptoms. In the present study, the inhibitory activities of extract from *K. parviflora* rhizome against 5α-reductase (5αR) were subjected. Furthermore, the effects of the extract from *K. parviflora* hizome in benign prostate hyperplasia (BPH) were studied using the model mice. **Materials and Methods:** Preparations of extracts from the rhizomes of *K. parviflora*, *Curcuma zedoaria* and *Zingiber officinale*, and methoxyflavones isolated from *K. parviflora* was used for 5αR inhibition assay. The effects of *K. parviflora* extract on growth suppression for the prostates and seminal vesicles were performed based on the Hershberger’s method. The *K. parviflora* extract was administered to castrated mice for 14 days. **Results:** *K. parviflora* extract showed more potent inhibitory activity on 5αR than *C. zedoaria* and *Z. officinale* extracts. The active principles were identified as 3,5,7,3′,4′-pentamethoxyflavone and 5,7,3′,4′-tetramethoxyflavone by activity guided fractionation. Furthermore, *K. parviflora* extract suppressed the weights of prostates and seminal vesicles in BPH model rats by daily administration for 14 days. **Conclusion:** These results indicate that *K. parviflora* extract can be a promising agent for the treatment of BPH.

**Key words:** 5α-reductase, benign prostate hyperplasia, *Kaempferia parviflora*, methoxyflavone

**INTRODUCTION**

Plant materials have been used for treatments of diseases in the Eastern countries, especially East Asia, for thousands of years. In the specific tribes in Thailand, *Kaempferia parviflora*, a Zingiberaceae plant, has been used a folk medicine called “Krachai Dum.” The rhizome and tincture of *K. parviflora* has been applied as medicine for general pain, colic gastrointestinal disorders, and male impotence. These various pharmacological activities of *K. parviflora* prompted researchers to elucidate its activities scientifically using the *in vivo* and *in vitro* assays. Among them, inhibition of P-glycoprotein function,[1] anti-plasmodial, anti-fungal and anti-mycobacterial effects,[2] cytotoxicity against various cancer cell lines,[3] anti-cholinesterase activity,[4] anti-allergic activity,[5] modulation of the function of multidrug resistance associated-proteins,[6] anti-gastric ulcer effect,[7] anti-obese activity,[8] anti-diabetes activity,[9,10] and inhibition of fat absorption[11] have been demonstrated. These multi-functional effects of *K. parviflora* makes it an attractive potential treatment for life-style-related diseases. Thus, continuous research to discover novel effects of *K. parviflora* on life-style-related diseases has been performed in our laboratory.

Among various life-style-related diseases, we first focused on anti-hyperuricemia activity based on inhibition on xanthine oxidase. Xanthine oxidase has been recognized as a key enzyme for producing uric acid and a treatment for gout. *K. parviflora* extract showed potent inhibitory activity compared to other Zingiberaceae plants used as crude drugs and the active principles were determined as 3,5,7,3′,4′-pentamethoxyflavone and 5,7,3′,4′-tetramethoxyflavone.[12] In addition, we focused on an improvement effect on blood fluidity. Stagnation of blood causes a loss of metabolism, obesity, and poor circulation. *K. parviflora* has been shown to have fibrinolysis activity and improved the blood fluidity in disseminated intravascular coagulation model rats.[13] Thus, we have been demonstrated some novel *K. parviflora* function and believe that other novel functions are yet to be revealed.
Benign prostate hyperplasia (BPH) is life-style-related illnesses caused by inappropriate diet habits and the social stress leading to hormone imbalance. The incidence of BPH is approximately 50-60% in males 40-60 years old and greater than 90% in men over 80 years. It also causes urinary tract obstruction and infection. Androgen plays an important role in the growth, and maintenance of normal prostate gland, function as well as in the development of BPH. The androgens testosterone and dihydrotestosterone (DHT) contribute to the onset of BPH. Testosterone is converted to DHT by 5α-reductase (5αR). DHT is a potent androgen whose and its action is mediated through binding to the androgen receptor (AR) in the prostate, which induces protein synthesis and abnormal growth of the prostate. Therefore, inhibition of 5αR could help prevent BPH. Finasteride, a potent 5αR inhibitor and flutamide, a binding inhibitor to AR are used as effective agents in BPH treatment. These drugs, however, are known to produce side-effects including impaired liver function, diarrhea, and headache. Alternatively, functional foods including natural products that show 5αR inhibitions may be useful in the prevention of BPH.

Some 5αR inhibitors from natural products have been discovered by our group, i.e., 12-methoxycarnosic acid in Rosmarinus officinalis leaf, ginsenoside Ro in the rhizome of red ginseng, kaikasaponin and soyasaponin in flowers of Pueraria thomsonii and fatty acids and ethinylestradiol in spores of Lycopodium japonicum.

In the present study, extract from K. parviflora rhizome was subjected to the inhibitory assay against 5αR along with other Zingiberaceae plants. K. parviflora showed potent activity and the active principle was revealed. Furthermore, a result on the improvement of BPH by K. parviflora using in vivo BPH model is described.

**MATERIALS AND METHODS**

**Materials**

Rhizomes of K. parviflora were purchased from Aoba trading Co. (Tokyo, Japan). Voucher specimens were deposited at the Faculty of Pharmacy, Kinki University. Reagents used in this study were of analytical grade and were purchased from Wako Pure Chemicals Industries (Osaka, Japan) or Nacalai Tesque (Kyoto, Japan) unless otherwise stated.

**Preparations of extracts and methoxyflavones**

Preparations of extracts from rhizomes of K. parviflora, Curcuma zedoaria and Zingiber officinale, and methoxyflavones were performed according to the methods previously reported.

**Inhibitory assay for 5αR**

The enzyme 5αR was prepared according to the method reported with modifications. Rats (Wistar, 9 weeks, 270-290 g) were purchased from Shimizu Laboratory Supplies Co., Ltd. (Kyoto, Japan), and were maintained at a constant temperature and humidity under a 12 h light/dark cycle for 11 days. Water and pellet chow (Labo MR stock, Nosan Corporation, Tokyo, Japan) were freely available. The epididymis was removed from 100 rats and homogenized with a blender in cooled physiological saline containing 0.25 M sucrose and protease inhibitor cocktail. Homogenates were filtered and centrifuged at 300 × g for 10 min, and the supernatants were centrifuged again under the same conditions to obtain crude enzyme the protein assay method (Bio-Rad Laboratories, Inc., Hercules, CA) and crude enzyme solution was diluted to 10 mg/ml and stored at −85°C until use.

The 5αR inhibition assay was performed as reported previously with minor modifications. The reaction solution containing 50% ethanol (50 μl) with various concentrations of test compounds, 600 μl of 100 mM Mcllvaine buffer (pH 5.0), 20 μl of testosterone (0.4 mM in propylene glycol [PG]-citrate/phosphate buffer, pH 5.0 [1:1 v/v]) and 110 μl of enzyme solution. Reactions were initiated by the addition of 20 μl of 34 mM nicotinamide adenine dinucleotide phosphate reduced form. The mixture was incubated at 37°C for 30 min. After addition of 1.0 ml of dichloromethane and 20 μl of ρ-hydroxybenzoate n-hexyl ester as an internal standard (IS), the organic layer was obtained by centrifugation (3000 × g for 3 min), and transferred to another tube and air dried. The residue was dissolved in 0.2 ml of methanol, and an aliquot of 30 μl was injected into an high performance liquid chromatography (HPLC) system under the following conditions: Column, YMC-Pack ODS-AM302 (4.6 i.d. × 150 mm); column temperature, 40°C; mobile phase, methanol/water (65:35, v/v); flow rate, 1.0 ml/min; detection, UV at 254 nm, tR of testosterone, 7 min, tR of IS, 14 min. The control-0-min tube received 1.0 ml of dichloromethane before addition of the enzyme solution, whereas, the control-30-min tube received 50 μl of methanol instead of the test sample. A similar procedure to that described previously was carried out for these control tubes. The 5αR inhibitory activity was determined from the following equation using the peak-area ratios (r = testosterone/IS). Finasteride (Tokyo Chemical, Tokyo, Japan) was used as a reference drug.

\[
\text{Inhibition (%) } = 100 \times \left( \frac{C_{\text{sample}}}{C_{\text{control}}} - 1 \right)
\]

C: Conversion rate (%) of testosterone to DHT

Csample (C for sample groups) = r of the test sample – r of control-30 min
\( C_{\text{control}} \) (C for control groups) = \( r \) of control-0 min – \( r \) of control-30 min.

**Animals**

Male Crj: CD Sprague-Dawley (SD) rats, which castrated at 6 weeks age and normal (not castrated) SD rats (7 weeks age) were purchased from Shimizu Laboratory Supplies (Kyoto, Japan). The rats were acclimatized for 1 week in an animal room, which is maintained by air-conditioning with lighting from 7 a.m. to 7 p.m. The temperature and humidity were controlled automatically. Laboratory pellet chow (Labo MR stock, Nihon Noso Kogyo, Tokyo, Tokyo, Japan) and water were freely available. All experimental protocols using animals were approved by the Committee for the Care and Use of Laboratory Animals at Kinki University.

**Animal treatments**

The growth suppression assay of prostates and seminal vesicles in castrated rats was performed based on the Hersherberger’s method.\(^{[27,28]}\) The castrated rats were randomized to four groups of 6 rats: (1) A negative control group receiving intraperitoneal administration (i.p) of olive oil and oral administration (p.o) of 100 \( \mu \)l of 50% PG, (2) testosterone propionate (TP) (2 mg/kg, i.p) and 100 \( \mu \)l of PG (p.o), (3) TP (2 mg/kg, i.p) and K. parviflora ext in PG (200 mg/kg, p.o) and (4) TP (2 mg/kg, i.p) and finasteride in PG (2 mg/kg, p.o). Non-treatment group (not castrated rats) was also prepared. The administrations were performed once a daily for 14 days.

**Sacrifice and evaluation of prostates and seminal vesicles weights**

The day after the last treatment (at the day 15 from the starting of administration), rats were sacrificed under anesthesia with pentobarbital (35 mg/kg). Their prostates and seminal vesicles were removed and weighted.

**Statistical analysis**

Data were evaluated statistically by Bonferroni/Dunn multiple range tests using a Microsoft Excel add-in software Statcel (Ver. 3, OMS publishing, Saitama, Japan). Significant differences were detected at \( P < 0.05 \) and 0.01.

## RESULTS AND METHODS

### Effects of K. parviflora, C. zedoaria and Z. officinale extracts on 5αR inhibition

Firstly, the inhibitory activity (conversion rate of testosterone to DHT) of the K. parviflora extract was studied compared with those of C. zedoaria and Z. officinale extracts on 5αR. The results are shown in Table 1. K. parviflora extract showed enzyme inhibition of 75.8% at 500 \( \mu \)g/ml while the values for the C. zedoaria and Z. officinale extracts were 28.2% and 21.1%, respectively. This result suggested that K. parviflora has the most potent activity and may be effective in the treatment of BPH.

### Effects of methoxyflavones from K. parviflora on 5αR

Secondly, the inhibitory activities of methoxyflavones from K. parviflora were examined since methoxyflavones are known to be multi-potential active compounds. The results are shown in Table 2. Among the compounds tested, 3, 5, 7, 3’, 4’-pentamethoxyflavone and 5, 7, 3’, 4’-tetramethoxyflavone showed the most potent inhibitory activities of 55.9% at 50 \( \mu \)M (Figure 1). Their IC\(_{50}\) values were 46.6 and 48.7 \( \mu \)M for 3, 5, 7, 3’, 4’-pentamethoxyflavone and 5, 7, 3’, 4’-tetramethoxyflavone, respectively. These results indicated that these two methoxyflavones were the most potent among the nine methoxyflavones.

### Effects of K. parviflora extract on rat prostate and seminal vesicle weights

The effects of K. parviflora extract on the growth of rat prostates and seminal vesicles were studied. The results are shown in Figure 2. The mean prostate weight/body weight of the group, which received PG (control group) was 145.0 \( \pm \) 30.7 mg/kg [Figure 2a]. The mean prostate weight/body weight of the group with BPH induced by TP injection was 1898.0 \( \pm \) 325.2 mg/kg, which was significantly higher than that of the control group (\( P < 0.01 \)). The mean prostate weight/body weight of the rats that received the K. parviflora extract (200 mg/kg) was 986.1 \( \pm \) 124.6 mg/kg. Compared with the BPH group, K. parviflora showed a significant reduction in prostate weight (\( P < 0.05 \)). The mean prostate weight/body weight of the finasteride-administered (2 mg/kg) rats was 742.3 \( \pm \) 84.0 mg/kg, which was significantly lower than the BPH group (\( P < 0.01 \)). The mean prostate weight/body weight of the non-castrated and treated rats was 397.0 \( \pm \) 61.9 mg/kg [Figure 2a].

### Table 1: Inhibitory effects of crude Zingiberaceae extracts on 5αR

| Extracts       | Concentration (µg/ml) | Conversion rate (%) | Inhibition (%) |
|----------------|-----------------------|---------------------|----------------|
| Control        | –                     | 41.2 \( \pm \) 0.8   | –              |
| K. parviflora  | 100                   | 23.0 \( \pm \) 0.6** | 44.1           |
|                | 200                   | 15.4 \( \pm \) 0.6** | 62.5           |
|                | 500                   | 10.0 \( \pm \) 0.6** | 75.8           |
| C. zedoaria    | 100                   | 30.8 \( \pm \) 0.2** | 25.1           |
|                | 200                   | 35.9 \( \pm \) 0.4** | 12.9           |
|                | 500                   | 28.6 \( \pm \) 0.6** | 28.2           |
| Z. officinale  | 100                   | 35.6 \( \pm \) 0.4** | 13.4           |
|                | 200                   | 32.2 \( \pm \) 0.3** | 16.9           |
|                | 500                   | 32.5 \( \pm \) 0.1** | 21.1           |
| Finasteride    | 250 (nM)              | 21.4 \( \pm \) 1.4** | 48.0           |

Each value represents the mean ± S.E. of triplicates. Significantly different from the control group at: **P<0.01.
Table 2: Inhibitory effects of methoxyflavones on 5αR

| Compounds                               | Concentration (μM) | Conversion rate (%) | Inhibition (%) |
|------------------------------------------|--------------------|---------------------|----------------|
| Control                                  | –                  | 35.3 ± 0.9          | –              |
| 3,5,7,3’,4’-pentamethoxyflavone          | 50                 | 15.6 ± 0.2**        | 55.9           |
| 5,7,3’,4’-tetramethoxyflavone            | 50                 | 15.4 ± 0.4**        | 55.9           |
| 3,5,7-trimethoxyflavone                  | 50                 | 23.0 ± 0.6**        | 34.9           |
| 5,7-dimethoxyflavone                     | 50                 | 24.3 ± 0.2**        | 31.3           |
| 5-hydroxy-3,7-dimethoxyflavone           | 50                 | 26.1 ± 0.0**        | 26.1           |
| 3,5,7,4’-tetramethoxyflavone             | 50                 | 27.0 ± 0.1**        | 23.5           |
| 5-hydroxy-3,7,3’,4’-tetramethoxyflavone  | 50                 | 28.7 ± 0.2**        | 18.7           |
| 5,7,4’-trimethoxyflavone                 | 50                 | 30.6 ± 0.4**        | 13.3           |
| 5-hydroxy-3,7,4’-trimethoxyflavone       | 50                 | 31.3 ± 0.9*         | 11.2           |
| Finasteride                              | 250 (nM)           | 16.3 ± 0.6**        | 53.7           |

Each value represents the mean ± S.E. of triplicates. Significantly different from the control group at; **P<0.01; *P<0.05

Figure 1: Chemical structures of 3,5,7,3’,4’-pentamethoxyflavone and 5,7,3’,4’-tetramethoxyflavone

Figure 2: Suppression of testosterone propionate-induced hyperplasia of prostates (a) and seminal vesicles (b) in castrated rats by *Kaempferia parviflora* extract. Values represent mean ± SE of n = 6. Significantly different from control group at #P < 0.01. Significantly different from negative control group at **P < 0.01
The mean seminal vesicles weight/body weight of the group, which received PG (control group) was 78.7 ± 16.7 mg/kg [Figure 2b]. The mean seminal vesicles weight/body weight of the group with BPH induced by TP injection was 1099.1 ± 73.9 mg/kg, which was significantly higher than that of the control group (P < 0.01). The mean seminal vesicles weight/body weight of the rats that received K. parviflora extract (200 mg/kg) was 737.2 ± 85.4 mg/kg. Compared with the BPH group, K. parviflora showed a significant reduction in seminal vesicle weight (P < 0.05). The mean seminal vesicles weight/body weight of the finasteride (2 mg/kg)-administered rats was 415.2 ± 36.0 mg/kg, which was significantly lower than that of the BPH group (P < 0.01). The mean seminal vesicles weight/body weight of the non-castrated and treated rats was 477.7 ± 28.3 mg/kg [Figure 2b].

In the present study, K. parviflora extract treatment resulted in a significant decrease in the weights of prostates and seminal vesicles in TP injected-castrated rats. These effects can be attributed to the inhibitory activity against 5αR exhibited by K. parviflora extract as shown in this manuscript.

Search for effective plant resources for the improvement of BPH has been performed extensively. Among them, *Serena repens*[^29][^30], *Ganoderma lucidum*[^31], *Lepidium meyenii* (Red Maca),[^32] banana peel,[^33] and *Echinacea purpurea*[^34] showed significant improvements of BPH. The results obtained in this study could have successfully presented that K. parviflora is a novel entry from Zingiberaceae plant and K. parviflora would be a promising candidate. Further, studies on the mode of action of K. parviflora extract are now underway.

**REFERENCES**

1. Patanasethanont D, Nagai J, Yumoto R, Murakami T, Sathanan K, Sripanidkulchai BO, et al. Effects of *Kaempferia parviflora* extracts and their flavone constituents on P-glycoprotein function. J Pharm Sci 2007;96:223-33.

2. Yenjai C, Prasanth K, Daoedee S, Wongpanich V, Kittakoop P. Bioactive flavonoids from *Kaempferia parviflora*. Fitoterapia 2004;75:89-92.

3. Yenjai C, Wanic S. Cytotoxicity against KB and NCI-H187 cell lines of modified flavonoids from *Kaempferia parviflora*. Bioorg Med Chem Lett 2010;20:2821-3.

4. Sawasdee P, Sabphon C, Sithiwongwanit D, Pokpol U. Anticholinesterase activity of 7-methoxyflavones isolated from *Kaempferia parviflora*. Phytother Res 2009;23:1792-4.

5. Tewtrakul S, Subhadhisaraksul S, Kummee S. Anti- allergic activity of compounds from *Kaempferia parviflora*. J Ethnopharmacol 2008;116:191-3.

6. Patanasethanont D, Nagai J, Matsuura C, Fukui K, Sathanan K, Sripanidkulchai BO, et al. Modulation of function of multidrug resistance associated-proteins by *Kaempferia parviflora* extracts and their components. Eur J Pharmacol 2007;566:67-74.

7. Rujjanawate C, Kanjanapothi D, Anomierdipison D, Pojanagaroon S. Anti-gastric ulcer effect of *Kaempferia parviflora*. J Ethnopharmacol 2005;102:120-2.

8. Shimada T, Horikawa T, Ikeya Y, Matsuio H, Kinoshita K, Taguchi T, et al. Preventive effect of *Kaempferia parviflora* ethyl acetate extract and its major components polymethoxyflavonoid on metabolic diseases. Fitoterapia 2011;82:1272-8.

9. Malakul W, Thirawarapan S, Ingkaninan K, Sawasdee P. Effects of *Kaempferia parviflora* wall. Ex boker on endothelial dysfunction in streptozotocin-induced diabetic rats. J Ethnopharmacol 2011;133:371-7.

10. Akase T, Shimada T, Terabayashi S, Ikeya Y, Sanada H, Aburada M. Antiobesity effects of *Kaempferia parviflora* in spontaneously obese type II diabetic mice. J Nat Med 2011;65:73-80.

11. Horikawa T, Shimada T, Okabe Y, Kinoshita K, Koyama K, Miyamoto K, et al. Polymethoxyflavonoids from *Kaempferia parviflora* induce adipogenesis on 3T3-L1 preadipocytes by regulating transcription factors at an early stage of differentiation. Biol Pharm Bull 2012;35:686-92.

12. Nakao K, Murata K, Deguchi T, Itho K, Fujita T, Higashino M, et al. Xanthine oxidase inhibitory activities and crystal structures of methoxyflavones from *Kaempferia parviflora* rhizome. Biol Pharm Bull 2011;34:1143-6.

13. Murata K, Deguchi T, Fujita T, Matsuha H. Improvement in blood fluidity by *Kaempferia parviflora* rhizome. J Nat Med in press.

14. Ziaa A, Rosenblum M, Crawford ED. Benign prostatic hyperplasia: An overview. Urology 1999;53:1-6.

15. Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ, et al. The endocrinology and developmental biology of the prostate. Endocr Rev 1987;8:338-62.

16. Lowe FC, McConnell JD, Hudson PB, Romas NA, Boake R, Lieber M, et al. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology 2003;61:791-6.

17. Marks LS. 5α-reductase: History and clinical importance. Rev Urol 2004;69:S11-21.

18. MacLean HE, Warner GL, Zajac JD. Localization of functional domains in the androgen receptor. J Steroid Biochem Mol Biol 1997;62:233-42.

19. Murata K, Noguchi K, Kondo M, Onishi M, Watanabe N, Okamura K, et al. Promotion of hair growth by *Rossmarinus officinalis* leaf extract. Phytother Res 2013;27:212-7.

20. Murata K, Takeshita F, Samukawa K, Tani T, Matsuha H. Effects of ginseng rhizome and ginsenoside Ro on testosterone 5α-reductase and hair re-growth in testosterone-treated mice. Phytother Res 2012;26:48-53.

21. Murata K, Noguchi K, Kondo M, Onishi M, Watanabe N, Okamura K, et al. Inhibitory activities of puerariae flos against testosterone 5α-reductase and its hair growth promotion activities. J Steroid Biochem Mol Biol 2012;66:158-65.

22. Matsuda H, Yamazaki M, Naruo S, Asanuma Y, Kubo M. Anti-androgenic activity of myricae cortex – Isolation of the androgen receptor. J Steroid Biochem Mol Biol 2011;62:233-42.

23. Matsuda H, Yamazaki M, Naruo S, Asanuma Y, Kubo M. Anti-androgenic activity of myricae cortex – Isolation of the androgen receptor. J Steroid Biochem Mol Biol 2011;62:233-42.

24. Matsuda H, Yamazaki M, Naruo S, Asanuma Y, Kubo M. Anti-androgenic activity of myricae cortex – Isolation of the androgen receptor. J Steroid Biochem Mol Biol 2011;62:233-42.

25. Matsuda H, Yamazaki M, Naruo S, Asanuma Y, Kubo M. Anti-androgenic activity of myricae cortex – Isolation of the androgen receptor. J Steroid Biochem Mol Biol 2011;62:233-42.
active constituents from bark of *Myrica rubra*. Biol Pharm Bull 2001;24:259-63.

26. Pratis K, O’Donnell L, Ooi GT, McLachlan RI, Robertson DM. Enzyme assay for 5alpha-reductase type 2 activity in the presence of 5alpha-reductase type 1 activity in rat testis. J Steroid Biochem Mol Biol 2000;75:75-82.

27. Yamasaki K, Sawaki M, Takatsuki M. Strain sensitivity differences in the Hershberger assay. Reprod Toxicol 2001;15:437-40.

28. Yamasaki K, Sawaki M, Ohta R, Okada H, Katayama S, Yamada T, *et al*. OECD validation of the Hershberger assay in Japan: Phase 2 dose response of methyltestosterone, viconzoloin, and p,p’-DDE. Environ Health Perspect 2003;111:1912-9.

29. Di Silverio F, Monti S, Sciarra A, Varasano PA, Martini C, Lanzara S, *et al*. Effects of long-term treatment with *Serenoa repens* (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate 1998;37:77-83.

30. Bayne CW, Donnelly F, Ross M, Habib FK. *Serenoa repens* (Permixon®): A 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH. Prostate 1999;40:232-41.

31. Fujita R, Liu J, Shimizu K, Konishi F, Noda K, Kumamoto S, *et al*. Anti-androgenic activities of *Ganoderma lucidum*. J Ethnopharmacol 2005;102:107-12.

32. Gasco M, Villegas L, Yucra S, Rubio J, Gonzales GF. Dose-response effect of red maca (*Lepidium meyenii*) on benign prostatic hyperplasia induced by testosterone enanthate. Phytomedicine 2007;14:460-4.

33. Akamine K, Koyama T, Yazawa K. Banana peel extract suppressed prostate gland enlargement in testosterone-treated mice. Biosci Biotechnol Biochem 2009;73:1911-4.

34. Skaudickas D, Kondrotas AJ, Kevelaitis E, Venskutonis PR. The effect of *Echinacea purpurea* (L.) Moench extract on experimental prostate hyperplasia. Phytother Res 2009;23:1474-8.